Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: Cell Immunol. 2010 Jul 17;265(1):65–73. doi: 10.1016/j.cellimm.2010.07.004

Figure 1. Treatment of tumor-bearing mice with the AGN2a-4P vaccine +/− anti-CD25 did not enhance survival.

Figure 1

(A) A/J mice were inoculated with 106 AGN2a cells in the subcutaneous space of the right hind flank (Day 0). Mice were treated with 250μg of anti-CD25 monoclonal antibody by intraperitoneal injection (Day 3) and/or two vaccinations of 2×106 AGN2a-4P cells given subcutaneously on Days 6 and 13. (B) Survival curves for groups of tumor-inoculated mice given no treatment (No Tx), vaccine only (Vac), or anti-CD25 and vaccine (Vac + αCD25). Tumor size was monitored and mice were considered as moribund when tumors exceeded 250mm2 in size. These data were combined from two independent experiments with 5 mice per group.